Your browser is not supported.

To view this content, please use one of the following browsers:

  • Microsoft Edge
  • Chrome
  • Safari
  • Home
  • Resources
  • Articles
  • ESC update on SGLT2 inhibitors in heart failure: position paper from the Heart Failure Association

ESC update on SGLT2 inhibitors in heart failure: position paper from the Heart Failure Association

ESC update on SGLT2 inhibitors in heart failure: position paper from the Heart Failure Association

The European Society of Cardiology (ESC) recently published its updated 2021 guidelines for the diagnosis and treatment of acute and chronic heart failure (HF)1 , with contribution of the Heart Failure Association (HFA) of the ESC, who earlier issued an updated position paper2 on the recommendations for the use of sodium-glucose co-transporter 2 (SGLT2) inhibitors in the prevention and treatment of heart failure.

The HFA recommendations are based on evidence from recent clinical trials outcomes, which further solidify previous evidence that SGLT2 inhibitors have a beneficial effect in reducing the risk of hospitalisation for HF in patients with type 2 diabetes (T2DM) and established cardiovascular disease or at high cardiovascular risk.

Accordingly, HFA recommends2 :

  • Canagliflozin, dapagliflozin, empagliflozin, or ertugliflozin are recommended for the prevention of HF hospitalization in patients with type 2 diabetes mellitus and established cardiovascular disease or at high cardiovascular risk.
  • Dapagliflozin or empagliflozin are recommended to reduce the combined risk of HF hospitalisation and cardiovascular death in symptomatic patients with HF and reduced ejection fraction already receiving guideline-directed medical therapy regardless of the presence of type 2 diabetes mellitus.

These recommendations highlight the role of SGLT2 inhibitors in heart failure.

References:

1. McDonagh TA, et al. European Heart Journal. 2021;42(36):3599–3726.

2. Seferović PM, et al. Eur J Heart Fail. 2020;22(11):1984-1986

Prescribing information for Invokana (canagliflozin)

T2DM Logo

Napp brings you recent and clinically relevant publications in the evolving field of Type 2 diabetes recommended by an international panel of specialists.

Editorial Board

Image
Dr. Salvatore A. De Cosmo's image

Dr. Salvatore A. De Cosmo

Head of Unit of Internal Medicine and Endocrinology, Scientific Institute “Casa Sollievo della Sofferenza” San Giovanni, Rotondo, Italy
,
Image
Dr. Juan José Gorgojo Martínez's image

Dr. Juan José Gorgojo Martínez

Head of Department of Endocrinology and Nutrition, University Hospital Fundación, Alcorcon, Madrid, Spain
,
Image
Dr. Patrick Holmes' image

Dr. Patrick Holmes

General Practitioner, St. George's Medical Practice, Darlington, UK

Editorial Board

Image
Dr. Salvatore A. De Cosmo's image

Dr. Salvatore A. De Cosmo

Head of Unit of Internal Medicine and Endocrinology, Scientific Institute “Casa Sollievo della Sofferenza” San Giovanni, Rotondo, Italy
Image
Dr. Juan José Gorgojo Martínez's image

Dr. Juan José Gorgojo Martínez

Head of Department of Endocrinology and Nutrition, University Hospital Fundación, Alcorcon, Madrid, Spain
Image
Dr. Patrick Holmes' image

Dr. Patrick Holmes

General Practitioner, St. George's Medical Practice, Darlington, UK

Publication under Spotlight

Heart Failure Association of the European Society of Cardiology Update on Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure

Eur J Heart

2020;22:1984-1986.

Authors: Petar M Seferovíc, Gabriele Fragasso, Mark Petrie, Wilfried Mullens, Roberto Ferrari, Thomas Thum, Johann Bauersachs, Stefan D Anker, Robin Ray, Yuksel Çavuşoğlu, Marija Polovina, Marco Metra, Giuseppe Ambrosio, Krishna Prasad, Jelena Seferovíc, Pardeep S Jhund, Giuseppe Dattilo, Jelena Čelutkiene, Massimo Piepoli, Brenda Moura, Ovidiu Chioncel, Tuvia Ben Gal, Stephane Heymans, Tiny Jaarsma, Loreena Hill, Yuri Lopatin, Alexander R Lyon, Piotr Ponikowski, Mitja Lainščak, Ewa Jankowska, Christian Mueller, Francesco Cosentino, Lars H Lund, Gerasimos S Filippatos, Frank Ruschitzka, Andrew JS Coats and Giuseppe MC Rosano

READ MORE